Form 4 holding
Interim CFO, Prin Acct Off
Neoleukin Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 21,637
- Estimated value
- $14,990
- Report date
- 11 Aug 2023
- Price
- $0.6928
- Ownership
- Direct
Sean Michael Smith - Interim CFO, Prin Acct Off at Neurogene Inc.
Issuer-level insider activity
- Role
- Interim CFO, Prin Acct Off
- Issuer ticker
- NGNE on Nasdaq
- Entity type
- Individual
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
No buys or sells have been reported by Sean Michael Smith since 25 Aug 2025
Reported holdings for Sean Michael Smith in Neurogene Inc.
Form 4 holding
Interim CFO, Prin Acct Off
Neoleukin Therapeutics, Inc.
- Security class
- Restricted Stock Units
- Shares / value
- 0
- Estimated value
- Report date
- 10 Aug 2023
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Transaction history for Sean Michael Smith in Neurogene Inc.
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.